Skip to main content

Table 4 Univariate analysis of patient and dosimetric characteristics and risk of radiation pneumonitis (n = 130)

From: Clinical outcome and predictors of survival and pneumonitis after stereotactic ablative radiotherapy for stage I non-small cell lung cancer

Characteristic

0–1 RP

Grade 2–3 RP

P Value

 

No. of Patients (%)

No. of Patients (%)

 

Sex

  

0.882

Male

59 (51.3)

8 (53.3)

 

Female

56 (48.7)

7 (46.7)

 

Age

  

0.310

≥74 years

62 (53.9)

6 (40.0)

 

<74 years

53 (46.1)

9 (60.0)

 

COPD stage

  

0.154

0–II

62 (53.9)

11 (73.3)

 

III–IV

53 (46.1)

4 (26.7)

 

History of other type of cancer

  

0.440

Yes

34 (29.6)

3 (20.0)

 

No

81 (70.4)

12 (80.0)

 

ECOG score before SABR

  

0.711

0–1

71 (61.7)

10 (66.7)

 

2–3

44 (38.3)

5 (33.3)

 

Gross tumor volume, cm3

  

0.375

≥9.6

55 (47.8)

9 (60.0)

 

<9.6

60 (52.2)

6 (40.0)

 

Planning target volume, cm3

  

0.151

≥73.2

54 (47.0)

10 (66.7)

 

<73.2

61 (53.0)

5 (33.3)

 

Tumor location

  

0.471

Peripheral

106 (92.2)

13 (86.7)

 

Central

9 (7.8)

2 (13.3)

 

Total lung volume*

V5

  

< 0.001

≥ 20.2%

51 (44.3)

14 (93.3)

 

< 20.2%

64 (55.7)

1 (6.7)

 

V10

  

< 0.001

≥ 14.3%

51 (44.3)

14 (93.3)

 

< 14.3%

64 (55.7)

1 (6.7)

 

V15

  

0.003

≥ 11.0%

52 (45.2)

13 (86.7)

 

< 11.0%

63 (54.8)

2 (13.3)

 

V20

 

0.055

 

≥ 8.5%

54 (47.0)

11 (73.3)

 

< 8.5%

61 (53.0)

4 (26.7)

 

V25

  

0.055

≥ 6.4%

54 (47.0)

11 (73.3)

 

< 6.4%

61 (53.0)

4 (26.7)

 

V30

  

0.003

≥ 5.0%

52 (45.2)

13 (86.7)

 

< 5.0%

63 (54.8)

2 (13.3)

 

V35

  

0.003

≥ 3.9%

52 (45.2)

13 (86.7)

 

< 3.9%

63 (54.8)

2 (13.3)

 

V40

  

0.013

≥ 3.1%

53 (46.1)

12 (80.0)

 

< 3.1%

62 (53.9)

3 (20.0)

 

Mean dose to total lung volume

  

0.013

≥ 5.05 Gy

53 (46.1)

12 (80.0)

 

< 5.05 Gy

62 (53.9)

3 (20.0)

 

Ipsilateral lung volume†

V5

  

< 0.001

≥ 37.7%

51 (44.3)

14 (93.3)

 

< 37.7%

64 (55.7)

1 (6.7)

 

V10

  

< 0.001

≥ 28.5%

51 (44.3)

14 (93.3)

 

< 28.5%

64 (55.7)

1 (6.7)

 

V15

  

< 0.001

≥ 21.9%

51 (44.3)

14 (93.3)

 

< 21.9%

64 (55.7)

1 (6.7)

 

V20

  

< 0.001

≥ 16.9%

51 (44.3)

14 (93.3)

 

< 16.9%

64 (55.7)

1 (6.7)

 

V25

  

0.003

≥ 13.1%

52 (45.2)

13 (86.7)

 

< 13.1%

63 (54.8)

2 (13.3)

 

V30

  

0.013

≥ 10.4%

53 (46.1)

12 (80.0)

 

< 10.4%

62 (53.9)

3 (20.0)

 

V35

  

0.003

≥ 8.1%

52 (45.2)

13 (86.7)

 

< 8.1%

63 (54.8)

2 (13.3)

 

V40

  

0.013

≥ 6.3%

53 (46.1)

12 (80.0)

 

< 6.3%

62 (53.9)

3 (20.0)

 

Mean dose to ipsilateral lung volume

  

< 0.001

≥9.14 Gy

51 (44.3)

14 (93.3)

 

<9.14 Gy

64 (55.7)

1 (6.7)

 
  1. * Defined as right plus left lungs minus the gross tumor volume.
  2. † Defined as the lung containing the lesion to be treated, minus the gross tumor volume.
  3. Abbreviations: RP, radiation pneumonitis; COPD, chronic obstructive pulmonary disease; ECOG, Eastern Cooperative Oncology Group; SABR, stereotactic ablative radiotherapy; Vx, volume of lung receiving =x Gy; GTV, gross tumor volume; MLD, mean lung dose.
Back to article page

Radiation Oncology

ISSN: 1748-717X

Contact us